BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bu J, Nair A, Iida M, Jeong WJ, Poellmann MJ, Mudd K, Kubiatowicz LJ, Liu EW, Wheeler DL, Hong S. An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy. Nano Lett 2020;20:4901-9. [PMID: 32510959 DOI: 10.1021/acs.nanolett.0c00953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Wang L, Zheng M, Zhu C, Wang G, Xia Y, Blumenthal EJ, Mao W, Wan Y. Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy. Bioact Mater 2022;9:251-65. [PMID: 34820569 DOI: 10.1016/j.bioactmat.2021.07.012] [Reference Citation Analysis]
2 Hu D, Zhang W, Tang J, Zhou Z, Liu X, Shen Y. Improving safety of cancer immunotherapy via delivery technology. Biomaterials 2021;265:120407. [PMID: 32992118 DOI: 10.1016/j.biomaterials.2020.120407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lee NK, Wang CJ, Lim J, Park W, Kwon HK, Kim SN, Kim TH, Park CG. Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities. Nano Converg 2021;8:24. [PMID: 34398322 DOI: 10.1186/s40580-021-00274-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 2021;14:85. [PMID: 34059100 DOI: 10.1186/s13045-021-01096-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jeong WJ, Bu J, Jafari R, Rehak P, Kubiatowicz LJ, Drelich AJ, Owen RH, Nair A, Rawding PA, Poellmann MJ, Hopkins CM, Král P, Hong S. Hierarchically Multivalent Peptide-Nanoparticle Architectures: A Systematic Approach to Engineer Surface Adhesion. Adv Sci (Weinh) 2021;:e2103098. [PMID: 34894089 DOI: 10.1002/advs.202103098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rawding PA, Bu J, Wang J, Kim DW, Drelich AJ, Kim Y, Hong S. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1752. [PMID: 34414690 DOI: 10.1002/wnan.1752] [Reference Citation Analysis]
7 Nair A, Bu J, Bugno J, Rawding PA, Kubiatowicz LJ, Jeong WJ, Hong S. Size-Dependent Drug Loading, Gene Complexation, Cell Uptake, and Transfection of a Novel Dendron-Lipid Nanoparticle for Drug/Gene Co-delivery. Biomacromolecules 2021. [PMID: 34319087 DOI: 10.1021/acs.biomac.1c00541] [Reference Citation Analysis]
8 Kim GB, Sung HD, Nam GH, Kim W, Kim S, Kang D, Lee EJ, Kim IS. Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation. J Control Release 2021;333:328-38. [PMID: 33794271 DOI: 10.1016/j.jconrel.2021.03.038] [Reference Citation Analysis]
9 Kim EH, Ning B, Kawamoto M, Miyatake H, Kobatake E, Ito Y, Akimoto J. Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction. J Mater Chem B 2020;8:10162-71. [PMID: 33095222 DOI: 10.1039/d0tb01729a] [Reference Citation Analysis]
10 Zuo S, Song J, Zhang J, He Z, Sun B, Sun J. Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what? Theranostics 2021;11:7471-87. [PMID: 34158861 DOI: 10.7150/thno.59953] [Reference Citation Analysis]
11 Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett 2021;16:173. [PMID: 34866166 DOI: 10.1186/s11671-021-03628-6] [Reference Citation Analysis]
12 Gao Y, Shen M, Shi X. Interaction of dendrimers with the immune system: An insight into cancer nanotheranostics. VIEW 2021;2:20200120. [DOI: 10.1002/viw.20200120] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Viana IMO, Roussel S, Defrêne J, Lima EM, Barabé F, Bertrand N. Innate and adaptive immune responses toward nanomedicines. Acta Pharm Sin B 2021;11:852-70. [PMID: 33747756 DOI: 10.1016/j.apsb.2021.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhu W, Bai Y, Zhang N, Yan J, Chen J, He Z, Sun Q, Pu Y, He B, Ye X. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. J Mater Chem B 2021;9:4201-10. [PMID: 33997867 DOI: 10.1039/d1tb00537e] [Reference Citation Analysis]
15 Bu J, Lee TH, Jeong WJ, Poellmann MJ, Mudd K, Eun HS, Liu EW, Hong S, Hyun SH. Enhanced detection of cell-free DNA (cfDNA) enables its use as a reliable biomarker for diagnosis and prognosis of gastric cancer. PLoS One 2020;15:e0242145. [PMID: 33264292 DOI: 10.1371/journal.pone.0242145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]